EnerSys Pays 166% Premium to Buy Ultralife for $320M Cash
ENS sits 44% above its 52-week low of $120.05.
Summary
EnerSys agreed to buy Ultralife at $16.00 a share in cash, valuing the deal at roughly $320M enterprise value — a 166% premium to Ultralife's Oct. 26 close. The price is a full takeout for a small defense-battery player and sets a hard ceiling near $16 for ULBI while the arb spread does the work. EnerSys funds it from cash on hand, so no dilution, and targets $15M-$20M of annual run-rate cost synergies within 18 months. The deal runs as a tender offer and needs regulatory clearance, with closing expected in Q1 2027, and holders owning about 40.3% of shares have signed tender and support agreements; either side owes a $10.3M termination fee, and the outside date is April 27, 2027. For EnerSys this is a bolt-on that extends its defense power platform; the $320M outlay is modest against its balance sheet and the synergy target is the number that decides whether it is accretive.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Ultralife holders owning about 40.3% of shares signed tender and support agreements; either side owes a $10.3M termination fee, and the outside date is April 27, 2027.
At the time of this announcement, ENS was trading at $173.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $120.05 to $244.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.